Pfizer Turns to Unusual Deal Structure to Buy Biohaven Drugs

Pfizer Inc.’s $11.6 billion acquisition of Biohaven Pharmaceutical Holding Co. included a rarely used structure that could become a larger part of Big Pharma’s playbook in light of a tougher antitrust regime.